VYNE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. With no Intellectia buy signals, bearish/weakening momentum (negative and expanding MACD histogram), and deteriorating profitability in the latest reported quarter, VYNE does not offer an attractive immediate-entry setup for an impatient buyer. I would avoid new buys here and treat it as a sell/stand-aside until momentum improves and price reclaims key resistance levels.
Trend/momentum is weak. MACD histogram (-0.00675) is below zero and expanding negatively, suggesting downside momentum is strengthening. RSI(6)=41.07 is neutral-to-soft (not oversold), so there is no strong mean-reversion buy signal. Moving averages are converging, implying indecision/possible consolidation, but with MACD negative the bias is still bearish. Key levels: immediate support S1=0.556 (price ~0.5618 is hovering just above it); if 0.556 breaks, next support is S2=0.546. Resistance is at Pivot=0.571 then R1=0.586; a more convincing near-term improvement would require holding above ~0.571 and pushing through 0.586. Pattern-based odds show only a 30% chance of gains with modest upside targets (about +3% to +4% across day/week/month), which is not compelling for a buy-now decision.
Intellectia Proprietary Trading Signals:
on a YoY basis (+39.67%), which is a constructive top-line datapoint (though from a low base).
No recent news catalysts to drive a near-term rerating. Technical momentum is weakening (MACD expanding negatively) while the stock sits close to support (S1=0.556), increasing breakdown risk. Profitability worsened in the latest quarter: net loss expanded and EPS declined YoY, which can weigh on sentiment in a small-cap biotech/therapeutics name.
Latest quarter: 2025/Q3. Revenue increased to $169K (+39.67% YoY), but losses widened: Net Income fell to -$7.28M (down -40.12% YoY) and EPS dropped to -0.17 (down -41.38% YoY). This combination implies growth is not translating into improving earnings power yet, which weakens the near-term investment case.
No analyst rating or price target change data provided, so no clear read on Wall Street consensus. Based on the data available: Pros would focus on the revenue uptick; cons are worsening net loss/EPS and weak technical momentum without a catalyst. Congress/politician trading: no recent congress trading data available; Hedge funds/insiders: neutral with no significant recent trends.
